TY - JOUR
T1 - Impact of COVID-19 on the Volume of Acute Stroke Admissions
T2 - A Nationwide Survey in Japan
AU - Yoshimoto, Takeshi
AU - Yamagami, Hiroshi
AU - Sakai, Nobuyuki
AU - Toyoda, Kazunori
AU - Hashimoto, Yoichiro
AU - Hirano, Teruyuki
AU - Iwama, Toru
AU - Goto, Rei
AU - Kimura, Kazumi
AU - Kuroda, Satoshi
AU - Matsumaru, Yuji
AU - Miyamoto, Susumu
AU - Ogasawara, Kuniaki
AU - Okada, Yasushi
AU - Shiokawa, Yoshiaki
AU - Takagi, Yasushi
AU - Tominaga, Teiji
AU - Uno, Masaaki
AU - Yoshimura, Shinichi
AU - Ohara, Nobuyuki
AU - Imamura, Hirotoshi
AU - Sakai, Chiaki
N1 - Funding Information:
This research was funded by the Health Labor Sciences Research Grant (20FA1201) of the Ministry of Health, Labour and Welfare Japan and endorsed by the Japan Stroke Society.
Funding Information:
All the following conflicts relate to this study. Yoshi-moto. T is supported by lecture fees from Takeda Pharmaceutical and Nippon Boehringer Ingelheim. Yamagami. H is supported by research grants from Bristol-Myers Squibb and lecture fees from Stryker, Terumo, Medtronic, Medico’s Hirata, Johnson & Johnson, Bayer Yakuhin, Daiichi-Sankyo, Bristol-Myers Squibb, Nippon Boehringer Ingelheim, and Otsuka Pharmaceutical. Sakai. N is supported by the following: a research grant from Biomedical Solutions, Neur-oVasc, and Terumo; lecturer’s fees from Asahi-Intec, Biomedical Solutions, Medtronic, and Terumo; and membership on the advisory boards for Johnson & Johnson, Med-tronic, and Terumo unrelated to this manuscript. Toyoda. K is supported by lecture fees from Daiichi Sankyo, Otsuka Pharmaceutical, Novartis Japan, Abbott Medical, Bayer Yakuhin, and Bristol-Myers Squibb. Hashimoto. Y, is supported by lecture fees from Daiichi Sankyo, Pfizer Japan, Bayer Yakuhin, and Otsuka Pharmaceutical. Hirano. T is supported by lecturer’s fee from Bayer Yakuhin, Nippon Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer. Iwama. T is supported by a research grant from Ohgaki Tokusyukai Hospital. Goto. R, none. Kimura. K is supported by lecture fees from Bristol-Myers Squibb, Nippon Boehringer Ingel-heim, Bayer Yakuhin, and Daiichi Sankyo as well as by research funding from Nippon Boehringer Ingelheim, Daiichi Sankyo, Pfizer Japan, Medtronic, and Teijin Pharma. Kuroda. S, none. Matsumaru. Y is supported by lecturer fees from Medtronic, Stryker, Terumo, Kaneka, E.P. Medical, Daiichi Sakyo, Takeda Pharmaceutical, and Bayer Yakuhin. Miyamoto. S is supported by the following: a research grant from Chugai Pharmaceutical and Philips Japan. Ogasawara. K, none. Okada. Y is supported by lecture fees from Bayer Yakuhin. Shiokawa. Y is supported by Dai-ichi Sankyo and lecturer’s fees from Ohtsuka Pharmaceutical. Takagi. Y, none. Tominaga. T, none. Uno. M, none. Yoshimura. S is supported by lecturer’s fees from Med-tronic, Johnson & Johnson, Terumo, Bristol-Myers Squibb, Otsuka Pharmaceutical, Boehringer Ingelheim, Daiichi Sankyo, Bayer Yakuhin, Sanofi, Biomedical Solutions, Kaneka Medics, and Stryker. Ohara. T, none. Imamura. H is supported by lecturer’s fees from Asahi-Intec, Johnson & Johnson, Medtronic, Stryker, and Terumo. Sakai. C, none. All authors who are members of the Japan Neurosurgical Society have registered online self-reported conflict of interest.
Publisher Copyright:
© 2022 The Japan Neurosurgical Society.
PY - 2022
Y1 - 2022
N2 - This study aimed to measure the impact of the COVID-19 pandemic on the volumes of annual stroke admissions compared with those before the pandemic in Japan. We conducted an observational, retrospective nationwide survey across 542 primary stroke centers in Japan. The annual admission volumes for acute stroke within 7 days from onset between 2019 as the pre-pandemic period and 2020 as the pandemic period were compared as a whole and separately by months during which the epidemic was serious and prefectures of high numbers of infected persons. The number of stroke patients declined from 182,660 in 2019 to 178,083 in 2020, with a reduction rate of 2.51% (95% confidence interval [CI], 2.58%-2.44%). The reduction rates were 1.92% (95% CI, 1.85%-2.00%; 127,979-125,522) for ischemic stroke, 3.88% (95% CI, 3.70%-4.07%, 41,906-40,278) for intracerebral hemorrhage, and 4.58% (95% CI, 4.23%-4.95%; 13,020-12,424) for subarachnoid hemorrhage. The admission volume declined by 5.60% (95% CI, 5.46%-5.74%) during the 7 months of 2020 when the epidemic was serious, whereas it increased in the remaining 5 months (2.01%; 95% CI, 1.91%-2.11%). The annual decline in the admission volume was predominant in the five prefectures with the largest numbers of infected people per mil-lion population (4.72%; 95% CI, 4.53%-4.92%). In conclusion, the acute stroke admission volume declined by 2.51% in 2020 relative to 2019 in Japan, especially during the months of high infection, and in highly infected prefectures. Overwhelmed healthcare systems and infection control practices may have been associated with the decline in the stroke admission volume during the COVID-19 pandemic.
AB - This study aimed to measure the impact of the COVID-19 pandemic on the volumes of annual stroke admissions compared with those before the pandemic in Japan. We conducted an observational, retrospective nationwide survey across 542 primary stroke centers in Japan. The annual admission volumes for acute stroke within 7 days from onset between 2019 as the pre-pandemic period and 2020 as the pandemic period were compared as a whole and separately by months during which the epidemic was serious and prefectures of high numbers of infected persons. The number of stroke patients declined from 182,660 in 2019 to 178,083 in 2020, with a reduction rate of 2.51% (95% confidence interval [CI], 2.58%-2.44%). The reduction rates were 1.92% (95% CI, 1.85%-2.00%; 127,979-125,522) for ischemic stroke, 3.88% (95% CI, 3.70%-4.07%, 41,906-40,278) for intracerebral hemorrhage, and 4.58% (95% CI, 4.23%-4.95%; 13,020-12,424) for subarachnoid hemorrhage. The admission volume declined by 5.60% (95% CI, 5.46%-5.74%) during the 7 months of 2020 when the epidemic was serious, whereas it increased in the remaining 5 months (2.01%; 95% CI, 1.91%-2.11%). The annual decline in the admission volume was predominant in the five prefectures with the largest numbers of infected people per mil-lion population (4.72%; 95% CI, 4.53%-4.92%). In conclusion, the acute stroke admission volume declined by 2.51% in 2020 relative to 2019 in Japan, especially during the months of high infection, and in highly infected prefectures. Overwhelmed healthcare systems and infection control practices may have been associated with the decline in the stroke admission volume during the COVID-19 pandemic.
KW - Japan
KW - admission
KW - coronavirus disease-2019
KW - nationwide survey
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85136115926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136115926&partnerID=8YFLogxK
U2 - 10.2176/jns-nmc.2022-0099
DO - 10.2176/jns-nmc.2022-0099
M3 - Article
C2 - 35753763
AN - SCOPUS:85136115926
VL - 62
SP - 369
EP - 376
JO - Neurologia Medico-Chirurgica
JF - Neurologia Medico-Chirurgica
SN - 0470-8105
IS - 8
ER -